Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;15(11):1299-1314.
doi: 10.1016/j.jiph.2022.10.011. Epub 2022 Oct 14.

Mucormycosis an added burden to Covid-19 Patients: An in-depth systematic review

Affiliations
Review

Mucormycosis an added burden to Covid-19 Patients: An in-depth systematic review

Naveed Nazir Shah et al. J Infect Public Health. 2022 Nov.

Abstract

As of 25th July, 2022, global Disease burden of 575,430,244 confirmed cases and over 6,403,511 deaths have been attributed to coronavirus disease 2019 (COVID-19). Co-infections/secondary infections continue to plague patients around the world as result of the co-morbidities like diabetes mellitus, biochemical changes caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) especially significant elevation in free iron levels, immune suppression caused by SARS-CoV-2, and indiscriminate use of systemic corticosteroids for the treatment of severe COVID-19 disease. In such circumstances, opportunistic fungal infections pose significant challenge for COVID-19 disease therapy in patients with other co-morbidities. Although COVID-19-associated Mucormycosis (CAM) has been widely recognized, currently extensive research is being conducted on mucormycosis. It has been widely agreed that patients undergoing corticosteroid therapy are highly susceptible for CAM, henceforth high index of screening and intensive care and management is need of an hour in order to have favorable outcomes in these patients. Diagnosis in such cases is often delayed and eventually the disease progresses quickly which poses added burden to clinician and increases patient load in critical care units of hospitals. A vast perusal of literature indicated that patients with diabetes mellitus and those with other co-morbidities might be highly vulnerable to develop mucormycosis. In the present work, the case series of three patients presented at Chest Disease Hospital Srinagar, Jammu and Kashmir infected with CAM has been described with their epidemiological data in supplementary section. All these cases were found to be affected with co-morbidity of Diabetes Mellitus (DM) and were under corticosteroid therapy. Furthermore, given the significant death rate linked with mucormycosis and the growing understanding of the diseases significance, systematic review of the literature on CAM has been discussed and we have attempted to discuss emerging CAM and related aspects of the disease.

Keywords: COVID-19; COVID-19 associated mucormycosis (CAM) and Co-morbidities; Coronavirus; Diabetes mellitus; Mucormycosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
: PRISMA methodology with flow chart of various step adopted for synthesis of present manuscript.
Fig. 2
Fig. 2
: An overview of epidemiology which includes risk factors, symptoms, diagnosis, and treatment of Mucormycosis associated COVID-19 patients. An overview of various promising diagnostic protocols employed for diagnosis of mucormycosis. Adopted from , .
Fig. 3
Fig. 3
Briefly summary of the optimal treatment approaches employed for treatment of mucormycosis. Adopted from , .

References

    1. Frazier K.M., et al. SARS-CoV-2 virus isolated from the mastoid and middle ear: implications for COVID-19 precautions during ear surgery. JAMA Otolaryngol Neck Surg. 2020;146(10):964–966. - PMC - PubMed
    1. Shah N.N., et al. An update on emerging therapeutics to combat COVID‐19. Basic Clin Pharmacol Toxicol. 2021;129(2):104–129. - PMC - PubMed
    1. Shah N.N., et al. Repurposing of Mycobacterium indicus pranii for the severe form of COVID‐19 patients in India: a cohort study. J Med Virol. 2022;94(5):1906–1919. - PMC - PubMed
    1. Oran D.P., Topol E.J. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann Intern Med. 2020;173(5):362–367. - PMC - PubMed
    1. Chen N., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. - PMC - PubMed

Substances